港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫美概念股

686.108

-31.133-4.34%

漲家數：4

跌家數：6

平家數：3

市盈率：- -

高：696.344

開：678.885

低：675.692

收：717.241

資料載入中...

四環醫藥(00460)4月28日斥資1088.67萬港元回購1617.4萬股

中證港股通醫療器械綜合指數報1194.94點，前十大權重包含時代天使等

首屆復鋭美學匯中外專家高峯論壇啓幕：聚焦肉毒毒素前沿，繪就醫美精準化新圖景

四環醫藥漲超4% 旗下聚乳酸面部填充劑“童顏針”獲批上市

四環醫藥(00460)出現大手買入280萬股，成交價$0.66，涉資184.8萬

阿斯达克财经

瑞麗醫美盤中異動下午盤股價大漲7.08%

瑞麗醫美(02135)股價上升7.08%，現價港幣$0.121

阿斯达克财经

復星醫藥(02196.HK)附屬組合夥投資醫療器械診斷

阿斯达克财经

三生製藥盤中異動早盤急速跳水9.37%報11.800港元

康哲藥業分拆德鎂醫藥上市，後者連續三年虧損

復星醫藥(02196)完成發行2025年度第一期中期票據(科創票據)

【四環醫藥(00460.HK)：渼顏空間自主研發的聚乳酸面部填充劑(童顏針)獲得國家藥監局上市批准】四環醫藥(00460.HK)發佈公告，集團旗下渼顏空間生物科技(吉林)有限公司自主研發的聚乳酸面部填充劑(該產品)正式獲得中國國家藥品監督管理局批准的第三類醫療器械註冊證，用以糾正中重度鼻唇溝皺紋。標誌着四環醫藥在再生醫美領域的又一重大突破，進一步鞏固了集團在高端醫美材料市場的技術領先地位。

四環醫藥：渼顏空間自主研發的童顏針獲得國家藥監局上市批准

三生製藥：非執董張皎娥減持 6000 股

三生製藥遭非執行董事張皎娥減持6000股每股作價12.88港元

昊海生物科技公佈第一季度業績歸母淨利約9031.21萬元同比減少7.41%

昊海生物科技(06826)公佈第一季度業績歸母淨利約9031.21萬元同比減少7.41%

復星醫藥擬設立河南復健加強大健康產業佈局

復星醫藥控股子公司復星平耀擬出資 490 萬元參設河南復健

市值兩百億藥企分拆！“皮膚”業務將上市……

国际金融报

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1593/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":686.1075,"timestamp":1745827736034,"preClose":717.24054,"halted":0,"volume":158238758,"delay":0,"changeRate":-0.043407,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-31.133057,"latestTime":"04-28 16:00:00","open":678.8851,"high":696.34436,"low":675.6922,"amount":1315776884,"amplitude":0.028794,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745890200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745803800000,1745812800000],[1745816400000,1745827200000]],"pbRate":1.255448,"peRate":19.315719,"turnoverRate":0.007817,"increases":3,"decrements":7,"flats":3,"marketCap":118158594152,"floatMarketCap":82270515368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":696.34436,"amplitude":0.028794,"preClose":717.24054,"low":675.6922,"pbRate":"1.255448","latestPrice":686.1075,"volume":158238758,"delay":0,"open":678.8851,"prevYearClose":571.87146,"prevWeekClose":717.241,"prevMonthClose":677.607,"prevQuarterClose":677.607,"fiveDayClose":661.02,"twentyDayClose":662.617,"sixtyDayClose":538.937,"secType":"PLATE","market":"HK","turnoverRate":0.007817,"peRate":19.315719,"marketCap":118158594152,"floatMarketCap":82270515368,"timestamp":1745827736034,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":4,"down":6,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530893478","title":"四環醫藥(00460)4月28日斥資1088.67萬港元回購1617.4萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2530893478","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530893478?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 17:53","pubTimestamp":1745834002,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，该公司于2025年4月28日斥资1088.67万港元回购1617.4万股股份，每股回购价格为0.66-0.68港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1593","BK1600","00460","BK1515"],"gpt_icon":0},{"id":"2530974424","title":"中證港股通醫療器械綜合指數報1194.94點，前十大權重包含時代天使等","url":"https://stock-news.laohu8.com/highlight/detail?id=2530974424","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530974424?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 17:07","pubTimestamp":1745831253,"startTime":"0","endTime":"0","summary":"数据统计显示，中证港股通医疗器械综合指数近一个月下跌3.48%，近三个月上涨15.43%，年至今上涨12.63%。从中证港股通医疗器械综合指数持仓样本的行业来看，医疗耗材占比79.10%、医疗设备占比16.57%、体外诊断占比4.34%。遇临时调整时，当中证港股通综合指数调整样本时，样本随之进行相应调整。若中证港股通综合指数样本有特殊事件发生，导致其行业归属发生变化，指数样本进行相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042817122894e5a36d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042817122894e5a36d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06699","09997","BK1574","BK1593","BK1587","09996","BK1583","BK1222","HSTECH","BK1100"],"gpt_icon":1},{"id":"2530880449","title":"首屆復鋭美學匯中外專家高峯論壇啓幕：聚焦肉毒毒素前沿，繪就醫美精準化新圖景","url":"https://stock-news.laohu8.com/highlight/detail?id=2530880449","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530880449?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 14:49","pubTimestamp":1745822940,"startTime":"0","endTime":"0","summary":"香港 2025年4月28日 /美通社/ -- 2025年4月27日，由中国整形美容协会指导的首届复锐美学汇中外专家高峰论坛盛大召开。本次论坛汇聚国内外顶尖医美专家，围绕肉毒毒素这一核心成分，深入探讨其在市场应用、科技研发、临床实践等多维度的发展，旨在为行业发展注入新动力，推动医美技术与理念的创新升级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4674018_ZH74018_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01696","BK1585","BK1593","BK1100"],"gpt_icon":0},{"id":"2530416914","title":"四環醫藥漲超4% 旗下聚乳酸面部填充劑“童顏針”獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2530416914","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530416914?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 14:47","pubTimestamp":1745822829,"startTime":"0","endTime":"0","summary":"消息面上，四环医药公布，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳酸面部填充剂(该产品)正式获得国家药品监督管理局批准的第三类医疗器械注册证，用以纠正中重度鼻唇沟皱纹。据悉，聚乳酸面部填充剂，市场简称“童颜针”，以左旋聚乳酸微球为核心成分，具有稳定的生物降解特性，可刺激自体胶原蛋白再生，实现“即时填充+长效再生”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042814495794e577df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042814495794e577df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","00460","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2530448594","title":"四環醫藥(00460)出現大手買入280萬股，成交價$0.66，涉資184.8萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2530448594","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530448594?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 14:00","pubTimestamp":1745820000,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午02:00出现大手买入，成交量为280万，成交价为港币$0.66，涉资184.8万。至目前为止，股价跌1.515%，今日最高价为$0.69，而最低价为$0.65，总成交量为2.302千万股，总成交金额港币$1.535千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2504287920/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1600","00460","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2530844383","title":"瑞麗醫美盤中異動 下午盤股價大漲7.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530844383","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530844383?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 13:58","pubTimestamp":1745819928,"startTime":"0","endTime":"0","summary":"2025年04月28日下午盘13时58分，瑞丽医美股票出现异动，股价快速上涨7.08%。截至发稿，该股报0.121港元/股，成交量1.4万股，换手率0.00%，振幅0.00%。瑞丽医美股票所在的医疗及医学美容服务行业中，整体跌幅为0.34%。其相关个股中，万嘉集团、奥思集团、亮晴控股涨幅较大，振幅较大的相关个股有亮晴控股、中国再生医学、熙康云医院，振幅分别为19.49%、9.52%、6.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428135848a6cb32df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428135848a6cb32df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02135","BK1593","BK1209"],"gpt_icon":0},{"id":"2530448307","title":"瑞麗醫美(02135)股價上升7.08%，現價港幣$0.121","url":"https://stock-news.laohu8.com/highlight/detail?id=2530448307","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530448307?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 13:58","pubTimestamp":1745819880,"startTime":"0","endTime":"0","summary":"[上升股]瑞丽医美(02135) 股价在下午01:58比前收市价上升7.08%，现股价为港币$0.121。至目前为止，今日最高价为$0.121，而最低价为$0.121。总成交量为1.4万股，总成交金额为港币$1610。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR250428909/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02135","BK1593","BK1209"],"gpt_icon":0},{"id":"2530349452","title":"復星醫藥(02196.HK)附屬組合夥投資醫療器械診斷","url":"https://stock-news.laohu8.com/highlight/detail?id=2530349452","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530349452?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 09:54","pubTimestamp":1745805240,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，附属复星平耀与上海复健、控股股东复星高科技及复曜智港签订合伙协议，拟共同设立河南复健，分别以现金出资490万、10万、290万、210万元人民币，权益占比分别为49%、1%、29%、21%。复星医药指，为加强大健康产业的布局，拟参与发起设立以中原地区为中心，以医疗器械诊断、生命科学、创新药及其上下游产业链为主要投资方向的股权投资基金。河南复健设立后，拟作为发起设立该股权投资基金的普通合伙人。(ha/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220221174704291_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220221174704291_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436237/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09997","09996","BK0239","BK0183","159883","BK1191","BK0187","BK1593","BK0096","BK1222","BK0028","BK0196","BK0188","BK1515","02196","BK1583","600196","BK0060","BK0012","BK1574","BK0175","BK1100"],"gpt_icon":0},{"id":"2530999704","title":"三生製藥盤中異動 早盤急速跳水9.37%報11.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530999704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530999704?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 09:39","pubTimestamp":1745804375,"startTime":"0","endTime":"0","summary":"2025年04月28日早盘09时39分，三生制药股票出现波动，股价快速跳水9.37%。截至发稿，该股报11.800港元/股，成交量2153.9万股，换手率0.90%，振幅7.07%。三生制药股票所在的药品行业中，整体跌幅为0.43%。其相关个股中，四环医药、海王英特龙、金嗓子涨幅较大，振幅较大的相关个股有三生制药、东阳光长江药业、翰森制药，振幅分别为7.07%、6.56%、6.07%。减持后其最新持股数目约为 1248.66 万股，最新持股比例为 0.52%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428093935a469c1d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428093935a469c1d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1593","01530","BK1161"],"gpt_icon":0},{"id":"2530453738","title":"康哲藥業分拆德鎂醫藥上市，後者連續三年虧損","url":"https://stock-news.laohu8.com/highlight/detail?id=2530453738","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530453738?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 21:38","pubTimestamp":1745761125,"startTime":"0","endTime":"0","summary":"港股上市公司康哲药业近日发布公告，将附属公司德镁医药股份分拆并于联交所主板独立上市。德镁医药主要负责康哲药业在国内的皮肤健康业务，最近三年均处亏损状态。目前，德镁医药已向联交所递交申请，康哲药业表示，分拆预计将通过由康哲药业以实物方式向股东分派其持有的所有德镁医药股份的方式实施。德镁医药为康哲药业附属公司，德镁医药90.8%权益由康哲药业实益拥有。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504273390338112.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504273390338112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BYV24P56.USD","BK1574","SG9999015945.SGD","09939","00867","IE00BMCWC346.EUR","SG9999015978.USD","BK1515","SG9999004220.SGD","LU2488822045.USD","SG9999015952.SGD","BK1161","BK1191","SG9999015986.USD","BK1593"],"gpt_icon":0},{"id":"2530431472","title":"復星醫藥(02196)完成發行2025年度第一期中期票據(科創票據)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530431472","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530431472?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:58","pubTimestamp":1745751538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，公司近日于通知书项下注册额度内完成2025年度第一期中期票据(科创票据)(本期中期票据)的发行。中期票据简称：25复星医药MTN001(科创票据)，实际发行总额人民币5亿元，期限2年。发行利率3.10%，起息日期2025年4月25日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK0239","159982","BK0028","BK0175","BK0096","600196","BK0183","BK0187","BK0188","BK0196","02196","BK1191","BK0060","BK1593","BK0012"],"gpt_icon":0},{"id":"2530243190","title":"【四環醫藥(00460.HK)：渼顏空間自主研發的聚乳酸面部填充劑(童顏針)獲得國家藥監局上市批准】四環醫藥(00460.HK)發佈公告，集團旗下渼顏空間生物科技(吉林)有限公司自主研發的聚乳酸面部填充劑(該產品)正式獲得中國國家藥品監督管理局批准的第三類醫療器械註冊證，用以糾正中重度鼻唇溝皺紋。標誌着四環醫藥在再生醫美領域的又一重大突破，進一步鞏固了集團在高端醫美材料市場的技術領先地位。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530243190","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530243190?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:57","pubTimestamp":1745751459,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK)发布公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳酸面部填充剂(该产品)正式获得中国国家药品监督管理局批准的第三类医疗器械注册证，用以纠正中重度鼻唇沟皱纹。标志着四环医药在再生医美领域的又一重大突破，进一步巩固了集团在高端医美材料市场的技术领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/27185749930234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1191","BK1593","159883","09996","BK1222","09997","000973.SH","BK1515","BK1574","159837","BK1600","00460","BK1100"],"gpt_icon":0},{"id":"2530395634","title":"四環醫藥：渼顏空間自主研發的童顏針獲得國家藥監局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2530395634","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530395634?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 18:26","pubTimestamp":1745749560,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨四环医药宣布，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚乳酸面部填充剂正式获得中国国家药品监督管理局批准的第三类医疗器械注册证，用以纠正中重度鼻唇沟皱纹。渼颜空间自主研发的“童颜针”，采用独特的专利技术，使其含有的左旋聚乳酸微球具有形态更规则、粒径分布更均一、品质稳定性更高的特点，显着提高产品的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427182830a4691469&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427182830a4691469&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","BK1600","00460","BK1191"],"gpt_icon":0},{"id":"2530101474","title":"三生製藥：非執董張皎娥減持 6000 股","url":"https://stock-news.laohu8.com/highlight/detail?id=2530101474","media":"和讯网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530101474?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 08:42","pubTimestamp":1745714565,"startTime":"0","endTime":"0","summary":"【香港联交所：4 月 24 日三生制药非执行董事张皎娥减持 6000 股】4 月 24 日，香港联交所最新资料显示，三生制药非执行董事张皎娥减持 6000 股。每股作价 12.88 港元，总金额约为 7.73 万港元。减持后其最新持股数目约为 1248.66 万股，最新持股比例为 0.52%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504271014099746e14a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504271014099746e14a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","01530","BK1593"],"gpt_icon":0},{"id":"2530868105","title":"三生製藥遭非執行董事張皎娥減持6000股 每股作價12.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530868105","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530868105?lang=zh_tw&edition=fundamental","pubTime":"2025-04-27 08:32","pubTimestamp":1745713920,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，4月24日，非执行董事张皎娥减持三生制药（01530）6000股，每股作价12.88港元，总金额约为7.73万港元。减持后最新持股数目约为1248.66万股，最新持股比例为0.52%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-27/doc-ineuqcqi7922093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2530571531","title":"昊海生物科技公佈第一季度業績 歸母淨利約9031.21萬元 同比減少7.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530571531","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530571531?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 00:32","pubTimestamp":1745598720,"startTime":"0","endTime":"0","summary":"昊海生物科技(06826)公布2025年第一季度业绩，营业收入约6.185亿元，同...昊海生物科技(06826)公布2025年第一季度业绩，营业收入约6.185亿元，同比减少4.25%;归属于上市公司股东的净利润约9031.21万元，同比减少7.41%;基本每股收益0.39元。追加内容本文作者可以追加内容哦 !","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426003333a6c846da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426003333a6c846da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06826","BK1593","BK1161"],"gpt_icon":0},{"id":"2530282131","title":"昊海生物科技(06826)公佈第一季度業績 歸母淨利約9031.21萬元 同比減少7.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530282131","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530282131?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 21:49","pubTimestamp":1745588992,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)公布2025年第一季度业绩，营业收入约6.185亿元，同比减少4.25%;归属于上市公司股东的净利润约9031.21万元，同比减少7.41%;基本每股收益0.39元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1593","06826"],"gpt_icon":0},{"id":"2530136358","title":"復星醫藥擬設立河南復健 加強大健康產業佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2530136358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530136358?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 20:56","pubTimestamp":1745585792,"startTime":"0","endTime":"0","summary":"格隆汇4月25日丨复星医药公告，于2025年4月25日，公司附属公司复星平耀与上海复健、复星高科技及复曜智港签订合伙协议，据此，各方拟共同设立河南复健。为加强大健康产业的布局，集团拟参与发起设立以中原地区为中心，以医疗器械诊断、生命科学、创新药及其上下游产业链为主要投资方向的股权投资基金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042520563297450d53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042520563297450d53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2530518756","title":"復星醫藥控股子公司復星平耀擬出資 490 萬元參設河南復健","url":"https://stock-news.laohu8.com/highlight/detail?id=2530518756","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530518756?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 20:14","pubTimestamp":1745583294,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 公布，2025 年 4 月 25 日，公司控股子公司复星平耀与上海复健、复星高科技、复曜智港拟分别出资人民币 490 万元、10 万元、290 万元和 210 万元共同设立河南复健。河南复健设立后，复星平耀、上海复健、复星高科技、复曜智港将分别持有其 49%、1%、29%和 21%的财产份额。为加强大健康产业的布局，该集团拟参与发起设立以中原地区为中心，以医疗器械诊断、生命科学、创新药及其上下游产业链为主要投资方向的股权投资基金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425202007974502f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425202007974502f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","02196","BK1191"],"gpt_icon":0},{"id":"2530188793","title":"市值兩百億藥企分拆！“皮膚”業務將上市……","url":"https://stock-news.laohu8.com/highlight/detail?id=2530188793","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530188793?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 18:28","pubTimestamp":1745576920,"startTime":"0","endTime":"0","summary":"近日，康哲药业(00867.HK)发布公告，建议将旗下皮肤业务附属公司德镁医药股份分拆并在港交所主板独立上市。同时，德镁医药有限公司（下称“德镁医药”）向港交所提交了上市申请，独家保荐人为华泰国际。需要指出的是，康哲药业此次分拆将以实物方式向其股东分派其持有的所有德镁医药股份，而德镁医药以介绍方式在香港主板上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504253388975578.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504253388975578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999015952.SGD","BK1574","SG9999015986.USD","BK4096","BK1161","BK1191","IE00BYV24P56.USD","SG9999004220.SGD","SG9999015945.SGD","BK1593","BK1515","09939","IE00BMCWC346.EUR","PN","00867","SG9999015978.USD","LU2488822045.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":114,"code":"91000000","status":"200"}]}}